Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease

Bibliography

• Grimwade D. The pathogenesis of acute promyelocytic leukemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol 1999;106:591-613
   PubMed Web of Science ®Google Scholar
• Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002;99:759-67
   PubMed Web of Science ®Google Scholar
• Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukemia. Lancet 1977;1:549-50
   PubMed Web of Science ®Google Scholar
• de The H, Chomienne C, Lanotte M, The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990;347:558-61
   PubMed Web of Science ®Google Scholar
• Mandelli F, Diverio D, Avvisati G, Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell’Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative groups. Blood 1997;90:1014-21
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1201-8
   Web of Science ®Google Scholar
• Fenaux P, Le Deley MC, Castaigne S, Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993;82:3241-9
   PubMed Web of Science ®Google Scholar
• Sanz MA. Treatment of acute promyelocytic leukemia. Hematology 2006;147-55
   PubMedGoogle Scholar
• Esteve J, Escoda L, Martin G, Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 2007;21:446-52
   PubMed Web of Science ®Google Scholar
• Lo Coco F, Diverio D, Avvisati G, Therapy off molecular relapse in acute promyelocytic leukemia. Blood 1999;94:2225-9
   PubMed Web of Science ®Google Scholar
• Tallman MS. The expanding role of arsenic in acute promyelocytic leukemia. Semin Hematol 2008;45:S25-9
   PubMed Web of Science ®Google Scholar
• Emadi A, Gore SD. Arsenic trioxide-an old drug rediscovered. Blood Rev 2010;24:191-9
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011;29:495-503
   PubMed Web of Science ®Google Scholar
• Huff J, Chan P, Nyska A. Is the human carcinogen arsenic carcinogenic to laboratory animals? Toxicol Sci 2000;55:17-23
   PubMed Web of Science ®Google Scholar
• Zhang TD, Chen GQ, Wang ZG, Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001;20:7146-53
   PubMed Web of Science ®Google Scholar
• Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 1997;89:3487-8
   PubMed Web of Science ®Google Scholar
• Litzow MR. Arsenic trioxide. Expert Opin Pharmacother 2008;9:1773-85
   PubMed Web of Science ®Google Scholar
• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15
   PubMed Web of Science ®Google Scholar
• Chen GQ, Zhu J, Shi XG, In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: as2O3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RAR. Blood 1996;88:1052-61
   PubMed Web of Science ®Google Scholar
• Fukai Y, Hirata M, Ueno M, Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Biol Pharm Bull 2006;29:1022-7
   PubMed Web of Science ®Google Scholar
• Au WY, Tam S, Fong BM, Kwong YL. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood 2008;112:3587-90
   PubMed Web of Science ®Google Scholar
• Chen GQ, Shi XG, Tang W, Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60
   PubMed Web of Science ®Google Scholar
• Soignet SL, Maslak P, Wang ZG, Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-8
   PubMed Web of Science ®Google Scholar
• Lallemand-Breitenbach V, Guillemin MC, Janin A, Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043-52
   PubMed Web of Science ®Google Scholar
• Kinjo K, Kikazi M, Muto A, Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 2000;14:431-8
   PubMed Web of Science ®Google Scholar
• Kitamura K, Minami Y, Yamamoto K, Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000;14:1743-50
   PubMed Web of Science ®Google Scholar
• Gianni M, de The H. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3 mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies. Leukemia 1999;13:739-49
   PubMed Web of Science ®Google Scholar
• Zhang W, Ohnishi K, Shigeno K, The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasm’s. Leukemia 1998;12:1383-91
   PubMed Web of Science ®Google Scholar
• Wang ZG, Rivi R, Delva L, Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARAalpha independent manner. Blood 1998;92:1497-504
   PubMed Web of Science ®Google Scholar
• McCabe MJ, Singh KP, Reddy SA, Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase. J Pharmacol Exp Ther 2000;295:724-33
   PubMed Web of Science ®Google Scholar
• Miller WH Jr, Schipper HM, Lee JS, Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903
   PubMed Web of Science ®Google Scholar
• Zhu J, Lallemand-Breitenbach V, de The H. Pathways of retinoic acid or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 2001;20:7257-65
   PubMed Web of Science ®Google Scholar
• Muller S, Miller WH, Dejean A. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. Blood 1998;92:4308-16
   PubMed Web of Science ®Google Scholar
• Lallemand-Breitenbach V, Zhu J, Puvion F, Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 2001;193:1361-71
   PubMed Web of Science ®Google Scholar
• Hayakawa F, Privalsky ML. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 2004;5:389-401
   PubMed Web of Science ®Google Scholar
• Costantini P, Belzacq AS, Vieira HL, Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2 independent permeability transition pore opening and apoptosis. Oncogene 2000;19:307-14
   PubMed Web of Science ®Google Scholar
• Larochette N, Decaudin D, Jacotot E, Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999;249:413-21
   PubMed Web of Science ®Google Scholar
• Li J, Chen P, Sinogeeva N, Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem 2002;277:49504-10
   PubMed Web of Science ®Google Scholar
• Davison K, Mann KK, Miller WH Jr, Arsenic trioxide: mechanisms of action. Semin Hematol 2002;39:3-7
   PubMed Web of Science ®Google Scholar
• Bernardini S, Nuccettelli M, Noguera NI, Role of GSTP-1 in mediating the effect of As2O3 in the acute promyelocytic leukemia cell line NB4. Ann Hematol 2006;85:681-7
   PubMed Web of Science ®Google Scholar
• Ninomiya M, Kajiguchi T, Yamamoto K, Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy. Haematologica 2006;91:1571-2
   PubMed Web of Science ®Google Scholar
• Chou WC, Chen HY, Yu SL, Arsenic suppresses gene expression in promyelocytic leukemia cells partly troughSp1 oxidation. Blood 2005;106:304-10
   PubMed Web of Science ®Google Scholar
• Mathieu J, Besancon F. Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells. Ann NY Acad Sci 2006;1090:203-8
   PubMed Web of Science ®Google Scholar
• Glienke W, Chow KU, Bauer N, Down-regulation of Wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma 2006;47:1629-38
   PubMed Web of Science ®Google Scholar
• Zheng PZ, Wang KK, Zhang QY, Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation7apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA 2005;102:7653-8
   PubMed Web of Science ®Google Scholar
• Ghaffari SH, Bashash D, Dizaji MZ, Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action. Tumour Biol 2012;33:157-72
   PubMedGoogle Scholar
• Jing Y, Wang L, Xia L, Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001;97:264-9
   PubMed Web of Science ®Google Scholar
• Zhu Q, Zhang JW, Zhu HQ, Synergic effects of arsenic trioxide and camp during acute promyelocytic leukemia cell maturation subtends a novel signalling cross-talk. Blood 2002;99:1014-22
   PubMed Web of Science ®Google Scholar
• Nasr R, Guillemin MC, Ferhi O, Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008;14:1333-42
   PubMed Web of Science ®Google Scholar
• Leung J, Pang A, Yuen WH, Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 2007;109:740-6
   PubMed Web of Science ®Google Scholar
• Sun HD, Ma L, Hu XC, Ai-LinI treated 32 cases of acute promyelocytic leukemia. Chin J Integr Chin West Med 1992;12:170-1
   Google Scholar
• Shen SZ, Chen GQ, Ni JH, Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60
   PubMed Web of Science ®Google Scholar
• Niu C, Yan H, Yu T, Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-24
   PubMed Web of Science ®Google Scholar
• Soignet SL, Frankel SR, Douer D, United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60
   PubMed Web of Science ®Google Scholar
• Lazo G, Kantarjian H, Estey E, Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 2003;97:2218-24
   PubMed Web of Science ®Google Scholar
• Au WY, Lie AK, Chim CS, Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukemia. Ann Oncol 2003;14:752-7
   PubMed Web of Science ®Google Scholar
• Raffoux E, Rousselot P, Poupon J, Combined treatment with arsenic trioxide and all-trans retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003;21:2326-34
   PubMed Web of Science ®Google Scholar
• Carmosino I, Latagliata R, Avvisati G, Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica 2004;89:615-17
   PubMed Web of Science ®Google Scholar
• Shigeno K, Naito K, Sahara N, Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updates outcomes of the phase II study and postremission therapies. Int J Hematol 2005;82:224-9
   PubMed Web of Science ®Google Scholar
• Aribi A, Kantarjian H, Estey E, Combination therapy with arsenic trioxide, all-trans retinoic acid, and gentuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 2007;109:1355-9
   PubMed Web of Science ®Google Scholar
• Shen ZX, Shi ZZ, Fang J, All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004;101:5328-35
   PubMed Web of Science ®Google Scholar
• Hu J, Liu YF, Wu CF, Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009;106:3342-7
   PubMed Web of Science ®Google Scholar
• Estey E, Garcia-Manero G, Ferrajoli A, Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107:3469-73
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Lakshmi KM, Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006;107:2627-32
   PubMed Web of Science ®Google Scholar
• Mathews V, Thomas M, Srivastava VM, Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica 2007;92:994-5
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Chendamarai E, Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia. long-term follow-up data. J Clin Oncol 2010;28:3866-71
   PubMed Web of Science ®Google Scholar
• Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006;17:131-4
   PubMed Web of Science ®Google Scholar
• Ghavamzadeh A, Alimoghaddam K, Rostami S, Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 2011;29:2753-7
   PubMed Web of Science ®Google Scholar
• Dai CW, Zhang GS, Shen JK, Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol 2009;121:1-8
   PubMed Web of Science ®Google Scholar
• Ravandi F, Estey E, Jones D, Effective treatment of acute promyelocytic leukemia with all-trans retinoic acid, arsenic trioxide, and gentuzumab ozogamicin. J Clin Oncol 2009;27:504-10
   PubMed Web of Science ®Google Scholar
• Powell BL, Moser B, Stock W, Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: north American Leukemia Intergroup Study C9710. Blood 2010;116:3751-7
   PubMed Web of Science ®Google Scholar
• Gore SD, Gojo I, Sekeres MA, Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 2010;28:1047-53
   PubMed Web of Science ®Google Scholar
• George B, Mathews V, Poonkuzhali B, Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia 2004;18:1587-90
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang Y, Li J, Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood 2010;115:1697-702
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu X, Zou Y, Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China. Int J Hematol 2011;93:199-205
   PubMed Web of Science ®Google Scholar
• Breccia M, Cicconi L, Minotti C, Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia. Haematologica 2011; Epub ahead of print
   Web of Science ®Google Scholar
• Huang SL, Guo AX, Xiang Y, Clinical study on the treatment of acute promyelocytic leukemia with composite Indigo Naturalis tablets. Chin J Hematol 1995;16:26-8
   Google Scholar
• Lu DP, Qiu JY, Jiang B, Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002;99:3136-43
   PubMed Web of Science ®Google Scholar
• Wu T, Zhao J, Jiang B, Tetra-arsenic tetra-sulfide containing triple-agent regimen as the first-line therapy for acute promyelocytic leukemia: expeditiously consecutive complete remission and improved disease-free survival. Blood 2007;110:abstract 591
   Web of Science ®Google Scholar
• Ghaffari SH, Shayan–Asl N, Jamialahmadi AH, Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Ann Oncol 2008;19:1927-34
   PubMed Web of Science ®Google Scholar
• Alimoghaddam K, Ghavamzadeh A, Rostami S, Risk factors for early mortality, relapse and overall survival in new cases of APL treated with arsenic trioxide. J Clin Oncol 2007;25:abstract 374
   Web of Science ®Google Scholar
• Tallman MS. What is the role of arsenic in newly diagnosed APL? Best Pract Res Clin Haematol 2008;21:659-66
   PubMed Web of Science ®Google Scholar
• Liu YJ, Wu DP, Liang JY, Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients. Med Oncol 2010; Epub ahead of print
   Web of Science ®Google Scholar
• Ferrara F, Finizio O, Izzo T, Autologous stem cell transplantation for patients with acute promyelocytic leukemia in second molecular remission. Anticancer Res 2010;30:3845-9
   PubMed Web of Science ®Google Scholar